Tyrosine kinase inhibitors (TKI), such as imatinib-mesylate (IM), are highly effective to suppress BCR/Abl enzymatic activity and to treat chronic phase CML patients. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.